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Myostatin is a potent negative regulator of muscle mass, i.e. high levels of myostatin 
induce loss of muscle. Surprisingly, severely obese humans and obese mice have elevated levels 
of serum myostatin, but the role of myostatin in controlling muscle mass during obesity is largely 
unknown. The aim of this study is to determine if obesity induced by a high-fat diet will decrease 
muscle mass or sensitize muscles to other factors that induce muscle atrophy. Thirty male 
C57BL/6 mice were divided into three groups; 12-wk control diet (CD), 9-wk control diet then 
3-wk high-fat diet (3wHF), and 12-wk high-fat diet (12wHF). At 10 weeks with each diet, the 
left sciatic nerve was cut (surgical denervation, a model of nerve damage), and contralateral 
sham operated. At 12 weeks, EDL, soleus, tibialis anterior (TA), plantaris, and gastrocnemius 
muscles were excised and weighed; body composition was measured by MRI; and serum 
myostatin was measured by ELISA. The EDL and soleus muscles were incubated and rates of 
protein degradation were determined by the net amount of tyrosine released. The TA muscles 
were cross-sectioned and mean fiber area estimated. As expected, the 12wHF resulted in a 
profound increase in fat mass (785%), with less in 3wHF (541%) and CD (216%). The 
concentration of myostatin in serum was between 1.5 to 2 fold higher (p ≤ 0.05) in the 12wHF 
group (705 pg/ml ± 79) than the 3wHF (420 pg/ml ± 36) and CD (316 pg/ml ± 18). In spite of 
	  this, there were no significant differences in muscle mass of the innervated muscles between 
diets. The percent atrophy due to denervation ranged from 15 to 39%, depending on the muscle, 
but there were no significant differences among diet groups, with the exception of greater 
atrophy (p ≤ 0.05) of the soleus muscle in the 3wHF group (26% versus 16% for CD and 15% 
for 12wHF). The rate of protein degradation was ~55 ηmol/g/hr for the innervated EDL muscles 
and ~75 ηmol/g/hr for the innervated soleus muscles. No significant differences existed between 
diet groups for either muscle. There were no significant differences between the diet groups for 
the rate of protein degradation of the denervated EDL muscles, but the rate of protein 
degradation for the denervated soleus muscle of the 3wkHF group was 30% faster than the CD 
and 12wkHF groups in accordance with the muscle mass findings. No significant differences in 
mean fiber area were found between diet groups among the innervated or denervated TA 
muscles. In summary, muscles of mice on a 12-week high-fat diet are exposed to higher 
myostatin but have the same mass and atrophy at the same rate as mice fed a control diet. This 
demonstrates that obesity may cause muscles to become resistant to the catabolic actions of 
myostatin. 
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CHAPTER 1: INTRODUCTION 
 
 Skeletal muscle is one the most metabolically active tissues in the human body, being the 
primary tissue responsible for both glucose and lipid oxidation1,2. Additionally, it provides the 
largest reservoir of amino acids for use during periods of fasting, sickness, and tissue trauma3–6. 
Perhaps because of these important metabolic roles of muscle, low levels of muscle mass have 
been identified as a comorbidity in numerous conditions such as AIDS, sepsis, heart failure, 
cancer, kidney failure, uncontrolled diabetes, sarcopenia, and severe tissue injury7–10. Therefore, 
identifying means to prevent or reverse muscle wasting is critical to human health.  
The prevalence of obesity has steadily increased in the United States over the last 20 
years11. Currently, 35.7% of the adult population is classified by their body mass index (BMI ≥ 
30 kg/m2) as being obese. Obesity is associated with metabolic inflexibility, defined as the 
inability to appropriately respond to alterations in substrate availability12. This phenomenon has 
been well documented in relation to glucose uptake and lipid oxidization12–14. However, a new 
characteristic of this inflexibility may be the inability to effectively mobilize amino acids15. For 
example, when muscles from a rodent hind limb were functionally overloaded to induce 
hypertrophy, the gain in muscle mass was significantly less in the obese rodents when compared 
to lean16. A possible reason for this blunted hypertrophy response could be elevated levels of the 
transforming growth factor myostatin documented in both human and animal models of 
obesity17,18. Myostatin is a potent negative regulator of muscle mass and is well known to reduce 
muscle size, increase rates of protein degradation, and decrease rates of protein synthesis19–21.  
The effect of obesity on muscle mass in general is largely unknown. One study indicates 
that muscles from mice fed a high-fat diet for 5 months have an elevated rate of protein 
degradation as well as significantly lower muscle weights22. However, considering that muscles 
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of obese rodents hypertrophy less than those of lean rodents, it might be predicted that muscles 
of the obese would atrophy to lesser extent than those of the lean when exposed to an atrophying 
stimulus such as denervation16. If this is true, understanding what mechanisms control muscle 
mass in the obese may provide a new area of study and the potential for the development of 
novel treatments to prevent muscle wasting in a wide range of muscle wasting syndromes. 
The purpose of this study is to determine if obesity changes the susceptibility of skeletal 
muscle to atrophy. The specific aim is to determine if C57BL/6 mice fed a high-fat diet for 3 or 
12-weeks will have an altered response to 14 days of sciatic nerve sectioning when compared to 
mice fed a diet of standard rodent chow. 
We will test the following hypotheses: 
1. The percent muscle mass lost from the denervated muscles will be less in the high-fat fed 
groups than in the standard chow fed group. 
2. The percent fiber cross-sectional area lost from the denervated tibialis anterior muscle 
will be lower in the high-fat fed groups than in the standard chow fed group. 
3. The rate of protein degradation of the denervated extensor digitorum longus and soleus 
muscles will be lower in the high-fat fed groups than in the standard chow fed group. 
	  	  	  
CHAPTER 2: REVIEW OF LITERATURE 
The Importance of Skeletal Muscle  
Skeletal muscle is one of the most vital tissues in the human body. In healthy adults, 
measurements taken by magnetic resonance imaging (MRI) have shown that muscle accounts for 
up to 40% of total body mass23. Muscle is also important for everyday movement, as it is the 
tissue that applies force to the skeletal system moving it about the environment24. In relation to 
this, it has been shown that total muscle mass has a positive correlation with quality of life in 
both the elderly and chronically ill25,26. Additionally, a negative correlation exists between 
overall muscle mass and the risk of falling and survival during chronic illness26,27. Therefore, 
maintaining muscle mass is critical for quality of life and prolonging mortality.  
  Skeletal muscle, in part because of its large size, is a major disposal site of metabolic 
substrates in the body. It alone accounts for ~20% of basal glucose uptake, which increases to 
~86% during periods hyperinsulinemia1. It is also the primary tissue involved in lipid oxidation 
with nearly 100% of the adenosine triphosphate (ATP) produced at rest coming from free fatty 
acids2.  Furthermore, it is the largest source of amino acids available to the human body during 
times of fasting3. For example, during the fasting state skeletal muscle is degraded in favor of 
providing amino acids to support protein synthesis for other tissues as well as precursors for 
gluconeogenesis3–6. When the amount of skeletal muscle decreases, the ability to perform these 
metabolic processes decreases as well. Since the capacity to uptake glucose, oxidize fatty acids, 
and mobilize amino acids decreases as whole body skeletal muscle decreases, these metabolic 
functions might explain the relationship between skeletal muscle mass and survival during 
chronic illness. 
 
	  4	  	  
Structure of Skeletal Muscle 
 Individual skeletal muscle cells look like long fibers with alternating areas of light 
and dark bands called striations24. Because of their fiber-like appearance they are commonly 
referred to as muscle fibers. They have similar structures to other cell types. For example, most 
cells have a plasma membrane and cytoplasm, whereas muscle fibers have a sarcolemma and 
sarcoplasm24. Additionally, muscle fibers have transverse tubules (t-tubules) and a sarcoplasmic 
reticulum instead of a golgi apparatus and endoplasmic reticulum24. A major difference between 
muscle fibers and other cells is that muscle fibers are multinucleated, meaning more than one 
nucleus exists per fiber24.  
Muscle fibers can be broken down into different structural components. Surrounding the 
muscle fiber is the sarcolemma24. Inside the sarcolemma are the nuclei, sarcoplasm, 
mitochondria, sarcoplasmic reticulum, t-tubules, and myofibrils24. Myofibrils consist of 
sarcomeres, the functional component of muscle fibers24. Sarcomeres are comprised of two 
contractile filaments, actin and myosin24. They line up end-to-end creating repetitive areas of 
overlapping and non-overlapping filaments creating the alternating areas of light and dark bands, 
thus giving skeletal muscle a striated appearance24.  Although all skeletal muscle has these basic 
elements, it is an extremely diverse tissue and is classified into different fiber types, each with its 
own characteristics and purpose. 
 
Muscles are Comprised of Different Fiber Types 
Skeletal muscle of small mammals can be classified into at least 4 fiber types; type I, type 
IIa, IIb, and type IIx. Type IIx fibers do not exist in skeletal muscle of humans or large 
mammals. Each fiber type is defined by their respective isoform of myosin heavy chain (MHC), 
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which can be broken down into type I, type IIa, type IIb, or type IIx28–30. The MHC protein 
consists of a tail and a globular head. The head binds to actin during contractions and contains 
the enzyme myosin ATPase. The rate at which ATP can be hydrolyzed depends on the activity 
level of this enzyme, which correlates with the type of MHC it resides on. Type I MHC has the 
slowest ATPase rate, while type IIa, type IIx, and type IIb are successively faster 31.  
Fiber types can be further classified by their oxidative capacity24. This relates to how 
much a muscle fiber relies on beta-oxidation for ATP instead of glycolysis24. Fibers with greater 
oxidative capacity, i.e. more mitochondria, are able to sustain production of ATP and therefore 
can contract for longer periods of time24. In other words, highly oxidative muscle fibers are 
fatigue resistant24. Type I fibers are generally more oxidative in nature than type II fibers and 
therefore are more fatigue resistant24. However, type IIa fibers are unique in the fact that they are 
capable of being highly oxidative as well as glycolytic24. Type IIb and type IIx fibers have less 
oxidative capacity and rely more heavily on glycolysis24. Therefore these fibers are the least 
resistant to fatigue24. 
A muscle fiber’s maximal shortening velocity (V0) depends on the rate at which ATP can 
be hydrolyzed32. The lower the activity level of myosin ATPase, the slower a particular fiber can 
contract32. In mammalian skeletal muscle, type I fibers have the lowest V0, where as type IIb 
fibers have the highest32. When considering rodent skeletal muscle, type IIx fibers contract 
slightly slower than type IIb fibers33.  
The specific function of a whole muscle determines the fiber distribution within it24. 
Muscles used to maintain posture, stabilize movement, or perform tasks requiring fine motor 
control will predominately be composed of type I fibers, whereas muscles used during powerful 
movements will have a high number of type II fibers24. The amount of heterogeneity, or variety 
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of muscle fiber types, per muscle varies from species to species. Humans have a relatively even 
distribution of fiber types regardless of the muscle’s role24. However, some animals, such as 
rodents, have muscles or sections of muscle that are composed predominantly of a single fiber 
type34. The extensor digitorum longus (EDL), tibialis anterior (TA), and plantaris muscles of a 
rodent are exclusively type II34. The majority of the gastrocnemius is also type II with a small 
percentage type I fibers, with the superficial medial portion being predominantly type IIb and the 
deep lateral portion being predominantly type IIa34. The soleus is the only muscle that has a 
significant percentage, ~58%, of fiber area occupied by type I fibers34. This kind of homogeneity 
makes rodents an ideal model for examining the effects of diet-induced obesity on protein 
metabolism in different fiber types. 
As previously discussed, muscles that maintain posture, stabilize movement, or execute 
delicate movements are primarily composed of type I fibers24. The physiological demands of 
these roles do not require a fiber that generates powerful, high-velocity contractions. Instead the 
fiber must be able to contract for long periods of time. Type I fibers are ideal for this role 
because their myosin ATPases only require a moderate network of t-tubules and sarcoplasmic 
reticula24. An additional characteristic of this fiber is that they have numerous, large 
mitochondria capable of supplying the ATP required for continuous muscle contractions24. To 
help facilitate delicate movements, several small motor units innervate type I fibers24. This 
allows for the precise activation of specific muscle fibers, which make fine movements 
possible24.  
Type IIa and type IIb fibers are recruited for powerful, high velocity movements like 
sprinting or jumping24. To accommodate this kind of movement these fibers have well developed 
t-tubules and sarcoplasmic reticula, which allow them to quickly transmit action potentials as 
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well as release and sequester high amounts of calcium ions24. The combination of high myosin 
ATPase activity and the ability to transport large amounts of calcium ions allow type II fibers to 
cycle through contractions much faster than type I fibers24. Additionally, not only do large motor 
units innervate type II fibers, but also one single motor unit innervates more muscle fibers24. This 
design allows for more fibers to be recruited at one time, increasing the amount of force the 
muscle can generate24. Skeletal muscles are composed of several different fiber types. Each fiber 
type serves a specific purpose and usually has characteristics specific to the fiber’s function. 
Because of this specificity, different fiber types may respond to the same stimuli in different 
ways. 
 
Muscle Fiber Size is Influenced by Multiple Stimuli 
Skeletal muscle fibers respond to stimuli by adapting structural components to better 
accommodate continued stimulus; this trait is known as plasticity24. Plasticity is fiber-type 
specific and has been documented for different types of training and atrophy. For example, when 
type I fibers are exposed to resistance training, the amount of hypertrophy, as measured by 
percent increase of cross-sectional area, is typically less than type II fibers35,36. In contrast, 
endurance training increases the diameter of type I fibers while having little or no effect on the 
size of type II fibers37. Endurance training has also been shown to increase capillary density and 
oxidative enzyme activities in both type I and type II fibers38. If the stimulus is intense enough, a 
small portion of fibers may cross from one fiber type to another. Type IIb and IIx fibers of mice 
have been documented to transform into type IIa fibers when exposed to a significant amount of 
endurance training39. In extreme circumstances, such as low frequency electrical stimulation, 
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type II fibers have adopted oxidative characteristics that closely resemble those of type I fibers39. 
However, this shift in fiber types is less clear in human muscle. 
Fiber-type specific atrophy is more complex. Not only do different fiber types respond to 
atrophy differently, but also different types of atrophy influence each fiber type in a different 
way. For example, in young rats, surgically denervating the soleus and plantaris muscles for ten 
days can reduce their masses by up to 33% and 31%, respectively41. When the muscles are 
exposed to a large dose of corticosteroids the plantaris will again lose up to 30% of its mass, but 
the soleus muscle will only lose around 10%41. If exposed to starvation, the plantaris once again 
will lose approximately 30% of its mass, while the soleus only loses around 8%42. This indicates 
that type I oxidative fibers appear to be sensitive to denervation (inactivity) induced atrophy, but 
not other atrophy causes. Since both fiber types are influenced by denervation to relatively the 
same degree, denervation is an excellent model to explore other factors that may induce fiber-
type differences during atrophy. 
A lesser-known area of fiber type-specific plasticity is how muscle fibers respond to 
obesity. A study investigating different fiber types in the rectus abdominus of lean and obese 
women found that obese women had a lower percentage of type I fibers and significantly more 
type IIb fibers43. It was also found that the amount of weight lost after gastric bypass surgery was 
directly correlated to the percentage of type I fibers of the patient43. A similar study examined 
fiber type differences between rodents who were prone to dietary obesity and those who were 
resistant44. It was found that obesity prone rodents had significantly less type I fibers in the 
medial head of their gastrocnemius both before and after a high-fat feeding period of four weeks 
than obesity resistant rodents44. These studies suggest that a lower percentage of type I fibers 
may increase an individual’s susceptibility of becoming obese. Alternatively, it is possible that 
	  9	  	  
the distribution fiber types may shift during obesity from type I to type II and that a reduction in 
weight may shift type II fibers to type I.    
A limited number of studies using rodent models of obesity have attempted to examine 
the effects of obesity on skeletal muscle. The results have been inconclusive. After 28 days of a 
high-fat diet, the amount of MHC type I protein in the quadriceps muscle was 5.1 times higher 
than those on the control diet45. Western blots were done on elements of the electron transport 
chain and revealed that the protein content of complexes I-V were significantly higher in the 
high-fat group45. These findings suggest that a short term high-fat diet may remodel skeletal 
muscle in a way that increases its oxidative capacity. In contrast, a similar study showed that a 5-
week high-fat diet failed to induce significant changes in fiber-type composition or muscle 
capillariztion in the medial gastrocnemius, soleus, and EDL46. Currently there are no studies 
investigating the influence of long term high-fat feedings, periods of 12 weeks or greater, on 
fiber-type specific changes in skeletal muscle. 
 
Role of Skeletal Muscle in Disease 
 Cachexia is a form of skeletal muscle wasting caused by an underlying illness47. It is 
commonly associated with conditions such as AIDS, sepsis, heart failure, cancer, kidney failure, 
uncontrolled diabetes, and severe tissue injury42. The amino acids lost from skeletal muscle 
presumably are used by other tissues during these conditions48. For example, the increased 
immune response requires a greater amount of amino acids to help rebuild tissue and synthesize 
antibodies48. In order to meet the elevated need for amino acids, protein from skeletal muscle is 
degraded at an increased rate48. In a fed state, and when healthy, amino acids absorbed from the 
digestive system replenish the lost amino acids through a relative increase in protein synthesis48. 
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Because of an increased degradation rate during cachexia, protein synthesis cannot keep up and 
skeletal muscle is lost48.  
Inflammation and the myokine Myostatin are thought to play key roles in cachexia. 
During chronic illness the body often enters a proinflammatory state in which cytokines, such as 
interleukin-6 and tumor necrosis factor-α, are produced49. Cytokines inhibit growth factors and 
stimulate skeletal muscle protein degradation at the same time49. Increased expression of 
myostatin is also common in patients suffering from muscle wasting7,50,51. Myostatin, which is 
produced by muscle, negatively regulates skeletal muscle growth by increasing the rete of 
protein degradation, decreasing the rate of protein synthesis, and inhibiting myoblast 
differentiation and proliferation20,21. The combination of increased inflammation and elevated 
myostatin results in an accelerated rate of muscle catabolism. 
 
Current Interventions for Muscle Wasting 
Maintaining skeletal muscle is vital during times of health, illness, and advancing age. 
Currently there are no proven pharmaceutical therapies available to treat muscle wasting once it 
begins. Early interventions of nutritional supplementation and appetite stimulation result in little 
to no improvements in quality of life or survival52. On the other hand, exercise training has 
shown potential for maintaining and increasing muscle mass, especially when the muscle lost is 
due to advancing age or disuse53. For patients with chronic illness it is often difficult to exercise 
due to decreased muscle mass and malnourishment brought on by disease53. However, if patients 
start exercising at the onset of the disease they have a better chance of maintaining muscle mass, 
with some populations being successful at increasing it53. 
Several pharmacological therapies are currently being investigated. Promising 
medications include Thalidomide and Celebrax, which target cytokines associated with the 
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proinflammatory state of disease54.  Current results have been a mixture of positives and 
negatives. While these medications have been successful in clinical trials, increasing muscle 
mass as well as improving strength and quality of life, they are often accompanied by adverse 
side effects making long-term administration difficult55,56.  
A second class of medications, Anabolic-androgenic steroids, is capable of stimulating 
anabolism of skeletal muscle and inhibiting glucocorticoid receptors. When androgen binds to its 
receptor, muscle protein synthesis is increased57. In contrast, when glucocorticoids bind to their 
receptors they result in the reduction of the rate of skeletal muscle protein synthesis and an 
increase in protein degradation57. Additionally, androgens are necessary for the production of 
Insulin-like Growth Factor I, which is a major stimulator of muscle protein synthesis57. These 
medications have been successful at increasing muscle mass in the chronically ill, but adverse 
side effects make them a high-risk option57. An alternative to steroid medications called selective 
androgen receptor modulators are currently being developed58. These medications promote 
muscle growth in the same manner as steroids but, presumably, with less side effects58. 
 A third area of treatment being developed involves inhibiting myostatin59,60. This 
approach has been effective in mice for treating muscular dystrophies61, sarcopenia62, and 
various forms of disuse atrophy63. Its potential for treating cachexia has not been extensively 
investigated. However, in rodents with lung cancer, the administration of a myostatin inhibitor 
resulted in the increase of muscle mass, cross-sectional area, maximal force production, and 
oxidative enzyme activity60. Although this approach appears to have potential, the few studies 
looking at myostatin inhibition in humans has not been promising64, and further research is 
needed. 
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The majority of interventions being developed today focus on stimulating muscle protein 
synthesis54. The converse approach is to look at the pathways regulating muscle protein 
degradation. Most models of cachexia occur via activation of the major intracellular degradation 
pathway, the ubiquitin-proteosome65. Therefore, if a medication is developed that could target 
directly, or indirectly, the activation of the proteasome it would be expected to be beneficial for 
preserving skeletal muscle in all forms of muscle wasting. 
 
Mechanisms Behind Protein Degradation 
 
 Muscle mass is regulated by a balance between protein synthesis and protein 
degradation65. If synthesis is down regulated or degradation is up regulated, atrophy occurs. The 
majority of muscle atrophy is caused by an increase in protein degradation65,66. Protein 
degradation in muscle occurs either by the ubiquitin/proteasome pathway or an 
autophagy/lysosomal pathway65,66.  
Protein degradation occurring via the ubiquitin proteasome pathway (UPP) involves the 
use of ubiquitin as a marker for specific proteins selected for degradation65. A series of enzymes, 
known as E3 ubiquitin ligases, are used for the activation and attachment of ubiquitin to specific 
proteins67–71. These enzymes facilitate protein degradation by physically conjugating the 
ubiquitin and protein together65. The main E3 ubiquitin ligases involved in the degradation of 
skeletal muscle proteins are Muscle Ring Finger-1 (MuRF1)67,71 and Atrogin-1 (MAFbx)68–70. 
MuRF1 is responsible for the degradation of several contractile components including myosin-
binding protein C, myosin light chain 1, myosin light chain 2, and MHC67,71. MAFbx is 
associated with breakdown of MyoD, a protein responsible for myoblast differentiation, and 
eukaryotic initiation factor 3 subunit 568–70. After proteins are conjugated with a chain of 
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ubiquitin molecules, they are fed through the protein degrading machine known as the 26S 
proteasome65. 
Proteins are also degraded by proteolytic enzymes found in lysosomes66. Here, portions 
of the cytoplasm and organelles are engulfed by vacuoles called autophagosomes66. The 
autophagosomes then fuse with the lysosome where their content is degraded by lysosomal 
enzymes66. This pathway is apparently not as specific as UPP, and the exact mechanisms for how 
proteins are selected for degradation is not well defined66. It is unknown how protein degradation 
is regulated during obesity. 
 
Mechanisms Driving Protein Synthesis 
Protein synthesis is stimulated by the insulin growth factor-1 (IGF-
1)/phophatidylinositaol-3 kinase (PI3K)/Akt pathway72. IGF-1 is a peptide growth factor that has 
autocine/paracrine action known to stimulate hypertrophy in skeletal muscle72. When IGF-1 
binds to it’s membrane receptor it initiates a signaling cascade of intracellular kinases resulting 
in the activation of a serine/threonine kinase called Akt72.  
Akt is the central protein involved in the regulation muscle of growth72. It has been 
reported in transgenic mice where Akt is constitutively active that skeletal muscle mass and cross 
sectional fiber area is higher than in wild type mice73. Akt’s activation leads to the activation of 
regulatory-associated protein of mTOR (RAPTOR) and mammalian target of rapamycin 
(mTOR), collectively known as TORC1. TORC1 then activates p70S6K, which promotes protein 
synthesis73. Simultaneously, the activation of Akt inhibits protein degradation by 
phosphorylating the transcription factor FOXO74. As long as FOXO is phosphorylated it is 
unable to enter the nucleus and thus cannot promote the expression of MuRF1 and MAfbx74. 
Conversely, if Akt is inactivated FOXO will not be phosphorylated and can then translocate to 
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the nucleus where it promotes protein degradation by increasing the expression of MuRF1 and 
MAfbx74.  
 
Obesity is Associated with Metabolic Inflexibility 
Obesity is a growing epidemic in the United States of America. As of 2010, 35.7% of 
Americans 20 years old or older were obese as defined by having a body mass index (BMI) of 30 
kg/m2 or greater11. The increasing prevalence of obesity is also present in America’s youth75. In 
children, age percentiles are used to evaluate obesity75. Here, obesity is considered having a BMI 
greater than or equal to the 95th percentile75. In 2010, 16.9% of all children between the age of 2 
and 19 years old met this criteria11. 
Obesity is associated with developing what is called metabolic inflexibility12. Metabolic 
flexibility refers to the ability to switch from one substrate to another when it comes to producing 
energy12. Obese individuals have a reduced ability to switch between substrates, even when the 
cellular environment favors one substrate over the other13,15. Insulin resistance is perhaps the 
most well documented metabolic inflexibility that occurs as a consequence of obesity14. When a 
cell becomes insulin resistant it requires increasingly higher concentrations of insulin to take up a 
given amount of glucose from the blood stream14. Additionally, these individuals have a 
remarkably reduced ability to oxidize lipids12. When muscle tissue from lean and obese subjects 
was analyzed for the capacity to oxidize lipids, obese participants oxidized ~52% less lipid on 
average than lean participants12.  
A reasonable conclusion is that since obese individuals are metabolically inflexible in 
regards to both glucose uptake and lipid oxidation, then perhaps deficits in the area of protein 
metabolism are present as well. Indeed, under conditions of hyperinsulinemia and 
hyperaminoacidemia, two stimuli which promote protein synthesis and inhibit protein 
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degradation, obese participants had a lowered inhibition of protein degradation and decreased 
stimulation of protein synthesis15. This suggests that obese individuals cannot regulate the 
balance between protein degradation and protein synthesis in the same manner as lean 
individuals.  
This topic has been further studied in animal models16,22,76. Lean and obese rodents had 
their Achilles tendon severed at the point of their gastrocnemius in order to overload their soleus 
muscle76. Both groups responded to the overload by increasing muscle mass76. However, the 
increase in mass of the obese mice was ~53% less than that of the lean mice76. In a similar study, 
mice were fed a high-fat diet for 14 weeks16. At the conclusion of the diet the mice had an 
ablation procedure, severing the gastrocnemius and soleus, resulting in the functional overload of 
the plantaris muscle16. After 14 days of functional overload the plantaris of the high-fat fed group 
weighed 20% less than the control diet16. 
This reduced ability to hypertrophy associated with obesity could be attributed to 
elevated levels of myostatin17,18. In humans, elevated levels of myostatin have been observed in 
muscle tissue of those who are extremely obese (BMI ≥ 40 kg/m2)17. In rodents, 12 weeks of a 
high-fat diet results in a significant increase in mRNA for muscle myostatin when compared to 
standard rodent chow fed controls18. However, whether these elevated levels of myostatin have 
any effect on protein metabolism is unknown and additional research is necessary before further 
conclusions can be made. 
There are a limited number of studies investigating the effect of a long-term high fat 
feeding on protein degradation. One study looked at rodents fed a high-fat diet for a period 
lasting 5 months. They observed slight decreases in mass of the EDL or soleus muscles for the 
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high-fat mice22. Additionally, the basal rate of protein degradation of the high-fat group was 
significantly elevated22.  
At this time there are no studies investigating how skeletal muscle of the obese responds 
to an atrophy stimulus. Given that moderately obese individuals cannot mobilize proteins in 
response to a hypertrophying stimulus16,76, it would be logical to expect that they would also 
have difficulty mobilizing proteins in response to atrophy. Further, if basal protein degradation is 
elevated, as occurs with very long-term obesity22, muscle might increase their rate of protein 
catabolism. Therefore, the duration of the high-fat diet, or extent of obesity, may play a critical 
role in determining how skeletal muscle mass is regulated. If obesity is in fact associated with a 
altered ability to mobilize amino acids in response to atrophy, further investigation into the 
causes may provide a new target area for medication development in the treatment of muscle 
wasting disease.
	  	  	  
 
CHAPTER 3: METHODOLOGY 
 
Experimental Animals  
Six week old, male C57BL/6 mice were purchased from Charles River Laboratories. This 
mouse strain was selected because of their well-known susceptibility to obesity induced by a 
high-fat diet16,18,22. In addition to weight gain, a high-fat diet results in blood glucose levels 
nearly twice the amount of mice fed a standard diet, indicating that the high-fat diet induces 
insulin resistance18. All mice were housed at the East Carolina University (ECU) Brody School 
of Medicine animal care facility. The mice were kept three to a cage whenever possible. They 
had ad libitum access to water and food and were kept on a 12:12 hour light:dark cycle. This 
project was approved by the ECU Animal Care and Use Committee (Animal Use Protocol 
#P073).  
 
Study Design 
A grand total of sixty mice were randomly separated into three diet conditions. A control 
diet, 12-week high-fat diet (12wkHF), and 3-week high-fat diet (3wkHF), each lasting a total of 
12 weeks (Figure 3.1). Diet duration was set at 12 weeks as it is a common model used to induce 
insulin resistance in the C57BL/6 mouse16,18. The control diet lasted the entire 12 weeks and 
mice were fed standard rat chow (Prolab, RMH 3000) where 14% of calories came from fat, 26% 
from protein, and 60% from carbohydrate. The 12wkHF diet also lasted all 12 weeks, but mice 
were fed a diet (Opensource Diets, D12492) where 60% of the calories came from fat, 20% from 
protein, and 20% from carbohydrate. The 3wkHF diet group was fed standard rat chow for the 
first 9 weeks and then switched to the high-fat diet for the remaining 3. This diet was designed 
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with the intent to examine the influence of a short term high-fat diet independent of the mice 
becoming insulin resistant. 
Twenty mice were assigned to each diet condition. At 10 weeks, ten were randomly 
selected from each group for surgical, unilateral sectioning of the sciatic nerve (see Surgical 
Procedures). This procedure was selected for its effectiveness at inducing rapid atrophy in 
muscles of the rodent hind limb41. After surgery, mice continued on their diets for an additional 2 
weeks so that tissue and blood samples were collected exactly 12 weeks after each mouse started 
their respective diet. The other ten mice of each diet group had surgery 11 weeks and two days 
into the diet, thus samples were collected from these mice with 5 days of denervation. Muscle-
specific data of the 5 day denervated mice will be reported elsewhere.  
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Figure 3.1. Six week old, male C57BL/6 mice were separated into three diet conditions (8-10 
per group). Each group underwent a unilateral denervation at 10 weeks, indicated by an arrow. 
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Body Composition  
 Body weight was obtained using an electronic Ohaus scale measuring to 0.1 grams. Each 
mouse was weighed every week of the study to monitor weight gained. Body composition was 
measured every third week to determine fat mass and fat-free mass. It was measured by a 
magnetic resonance imager (EchoMRI 700 Body Composition Analyzer) capable of measuring 
to 0.01 grams. At the end of this study there were no significant differences in body weight, fat 
mass, and fat-free mass between mice in a respective diet group undergoing the 14-day 
denervation and those undergoing a 5-day denervation. In light of this, all weight and body 
composition measurements were pooled by diet condition.  
 
Surgical Procedures 
Mice were taken to a dedicated surgical room and anesthetized with isoflurane (Webster 
Veterinary). After removing the hair the on the lateral surface of the hind limb the bare skin was 
disinfected with iodine. An incision no larger than 5 mm was made at approximately mid-femur. 
Using blunt dissection, the quadriceps muscles were moved exposing the sciatic nerve. While the 
sciatic nerve was exposed, a 2 mm section was cut and removed to prevent nerve regrowth. The 
skin was then closed with surgical glue (3M Vetbond Tissue Adhesive). A sham surgery was 
performed on the contralateral limb. All steps for the sham surgery were identical to the 
denervation surgery with the exception of the sciatic nerve being cut and removed. This 
procedure is well characterized for inducing rapid atrophy in all muscle groups below the knee41. 
A subcutaneous dose of Buprenex (0.01mL/g) was given immediately post surgery as an 
analgesic. 
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Tissue Samples 
Mice were euthanized using a lethal dose of ketamine followed by cervical dislocation 
and pneumothorax once all samples had been collected. The gastrocnemius, tibialis anterior 
(TA), plantaris, extensor digitorum longus (EDL), and soleus muscles were collected along with 
a sample of whole blood from the abdominal aorta. All muscles were weighed immediately using 
an analytical balance measuring to 0.01 milligrams. The gastrocnemius and plantaris were then 
put in cryogenic tubes, flash frozen with liquid nitrogen, and then stored at -80°C. The EDL and 
soleus were immediately washed and prepared for measuring rates of protein degradation (see 
below). The TA was used to measure mean fiber area (see below). Since the rapid freezing 
nature of liquid nitrogen can cause artifacts within the muscle, the TA was instead frozen with 
isopentene cooled by liquid nitrogen. It was then stored in a cryogenic tube at -80°C.  
Whole blood was collected with a syringe from the abdominal aorta and then transferred 
to an eppendorf tube. The blood was left on ice until sufficient clotting had occurred. Once 
clotted, the blood was spun down at 5000 rpm for eight minutes to separate the red blood cells 
and from the plasma. The plasma was siphoned off and transferred to a clean eppendorf tube, 
which was immediately stored at -80°C. The red blood cells were discarded.     
 
Rate of Protein Degradation 
Rates of protein degradation were determined by measuring the amount of tyrosine 
released by muscles incubated at resting length77. Since tyrosine is neither synthesized nor 
degraded in skeletal muscle, the net accumulation of this amino acid in the medium reflects the 
net degradation of cell proteins77.  
In brief, each EDL and soleus muscle was washed in a 15 ml pyrex flask with 
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approximately 10 ml of Krebs henseleit buffer/ 5 mM  glucose/ 0.15 mM pyruvate gased with 
95% O2 /5% CO2. The muscles were then blotted dry, weighed and recorded to the nearest 0.1 
miligrams, and secured with a custom plastic clip at approximately resting length. The clip was 
then placed, muscle side down, in the pre-incubation well for 30 minutes with 3 ml of Krebs 
henseleit buffer/ 5 mM  glucose/ 0.15 mM pyruvate. During the pre-incubation, the well was 
covered and continuously gased with 95% O2 /5% CO2, and maintained at 37°C. Immediately 
before the 30 minutes expired, 3 ml of heated, bubbled Krebs henseleit buffer/ 5 mM glucose/ 
0.15 mM pyruvate containing 0.5 mM cyclohexamide (a protein synthesis inhibitor) was added 
to the incubation well. Once the 30 minutes of pre-incubation expired, the muscles were 
removed, blotted, and placed in the gassed incubation well. After 2 hours, 2 mL of the final 
incubation media was removed and added to a cryogenic tube with 0.5 mL 1N perchloric acid to 
precipitate proteins. These samples were then stored at -80°C until a time when the tyrosine 
concentration could be measured. The muscles were also removed after 2 hours and blotted dry, 
and then frozen in liquid nitrogen and stored in cryogenic tubes at -80°C.  
Tyrosine was measured by first derivitizing the samples with Waters AccQTag 
technology and then quantifying the derivitized amino acid using a Waters Aquity Ultra 
Performance Liquid Chromatograph. Rates of protein degradation are given as pmol tyrosine per 
mg muscle per two hours.  
 
Mean Fiber Area 
Serial cross sections of each TA were obtained using a cryostat-microtome (Microm HM 
550). The frozen TA muscles were placed in the cutting chamber, which was set at -20°C. Once 
the temperature of the TA equilibrated with the temperature of the cutting chamber, it was cut in 
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two at the muscle belly using a razor blade cooled to -20°C. The uncut end was fixed to a cutting 
chuck with a dime-sized portion of O.C.T. compound (Tissue-Tek). After setting the cutting 
platform, a total of three 10 µm cross-sections were obtained per muscle. Four muscles were able 
to fit per slide.  
After the desired number of cross-sections were obtained, the slides were left at room 
temperature for 30 minutes or until the cross-sections dried. A hydrophobic marker was used to 
make a barrier encircling all of the cross sections. A solution of 0.1% Triton-X100/ 1 X 
phosphate buffered saline (1 X PBS) was made and 200 µL of it pipetted onto each set of cross-
sections. Triton-X100 is a detergent capable of denaturing some of the membrane proteins, 
making the cross-sections more permeable to a blocking solution. After 2 minutes of incubating 
the slides were washed one time in 1 X PBS for five minutes. After washing, the slides were 
removed and blotted dry. Once dried, 200 µl of a blocking solution consisting of 1 X PBS/ 0.5% 
Bovine Serum Albumin (BSA)/ 10% Rat Serum was pipetted onto each set of cross-sections. 
The blocking solution prevents nonspecific binding of the primary antibody. The slides were 
then incubated at room temperature for 20 minutes.  
During the 20-minute incubation, a solution of 1 X PBS/ 0.5% BSA/ 2% Rat Serum was 
combined with a primary antibody for the protein laminin (Sigma-Aldrich Anti-Laminin 
antibody produced in rabbit, CAT.# L9393) in a working ratio of 1:500. After removal of the 
blocking solution, 200 µl of the diluted primary antibodies were pipetted onto each set of cross-
sections. The slides were then incubated overnight at 4°C in a humidifier. 
On day two, the slides were removed from 4°C and washed in 1 X PBS 3 times for 5 
minutes each. During the wash, a solution of 1 X PBS/ 0.5% BSA/ 2% Rat Serum was combined 
with the secondary antibody (Invitorgen Alexa Fluor® 546 Goat Anti-Rabbit IgG (H+L), CAT.# 
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A11010) in a working ratio of 1:250. After the final wash, 200 µL of the diluted secondary 
antibody was pipetted onto each set of cross-sections. The slides were then incubated in 
complete darkness at room temperature for 1 hour. The slides then were washed in complete 
darkness 3 times in 1 X PBS for 5 minutes each.  
After the final wash, the slides were removed and blotted dry with a kimwipe. Particular 
care was taken during this step to ensure that the cross-section did not get over blotted and then 
dry out. After blotting, a drop of mounting media containing DAPI (Invitrogen SlowFade® Gold 
Antifade Reagent with DAPI, CAT.# S36939), which stains for nuclear DNA, was placed 
directly on each set of cross-sections. A slide cover slip was then carefully placed on top of the 
slide and sealed using fingernail polish. At this point the cross-sections were ready for 
imagining.   
Laminin is a protein located on the sarcolemma, the outer membrane of a muscle fiber. 
By labeling this protein with a fluorescent antibody it outlines each individual fiber in the cross-
section. Images of this antibody were captured by a fluorescent capable microscope (Leica 
Microsystems) and Simple PCI 6 imaging software. The imagines were taken with a 10 X 
objective, which allowed for at least 300 fibers to be captured per image. Four to five images 
were taken per muscle. Mean fiber area was then calculated using the software program 
ImageJ78, which was downloaded from the National Institutes of Health website. Mean fiber area 
was calculated for each muscle and reported as µm2.   
 
Blood Glucose, Serum Insulin, and Serum Myostatin 
 Prior to euthanization, a small incision was made at the tip of the tail and a small drop of 
blood collected on a test strip (OneTouch Ultra Blue) and read using a glucometer (OneTouch 
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Ultra 2). Blood glucose was reported in mg/dL. Serum insulin was measured using an enzyme-
linked immunosorbent assay (ELISA) kit for rat / mouse insulin (Millipore, CAT.# EZRMI-
13K). A concentration curve ranging from 0.2 ng/mL to 10 ng/mL was generated from the 
standards provided by the ELISA kit. The ELISA protocol was followed exactly as directed by 
the manufacturer. The plate was read using a microplate reader (Spectramax M4) at an 
absorbance of 450 nm and 590 nm. The difference of absorbance was recorded. The amount of 
insulin in ng/mL was calculated relative to the standard curve. 
Serum myostatin was also measured using an ELISA kit for mouse myostatin (USCN 
Life Science Inc., CAT.# E9153Mu). A standard concentration curve ranging from 78 ρg/mL to 
5000 ρg/mL was generated from the stock solution and standard diluent supplied with the ELIZA 
kit. Serum samples were prepared as a 10 fold dilution, combining 20 µL of serum with 180 µL 
of 1 X PBS. The ELISA protocol was followed exactly as directed by the manufacturer. The 
plate was read using a microplate reader (Spectramax M4) at an absorbance of 450 nm. The 
amount of myostatin in ρg/mL was calculated relative to the standard curve. 
 
Calculations for Percent Atrophy and Percent Water  
The amount of muscle mass lost was calculated by taking the innervated wet weight, 
subtracting the denervated wet weight, dividing the difference by the innervated wet weight, and 
multiplying by 100 to get a percent atrophy.  
Low-grade inflammation is a common condition associated with a high-fat diet22,79. 
Inflammation can lead to edema, making it possible that any muscle mass lost may have been 
replaced by water. To account for this the EDL and soleus muscles were freeze-dried 
(LABCONCO) overnight. By taking the muscle’s wet weight, subtracting its dry weight, 
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dividing the difference by the wet weight, and then multiplying by 100 a percentage of water was 
calculated. Water can account for as much as 80% of a muscle’s mass80. If the percentage of 
water in the denervated muscles exceeded 80%, it is possible that their wet weights may have 
been inflated by excess water.    
Statistical Analysis 
 All response variables in this study were quantitative. There was one explanatory 
variable, diet condition, which was a categorical variable with three levels making an analysis of 
variance the appropriate statistical analysis to determine if there were any differences in the 
sample means. Alpha was set at p ≤ 0.05. A Tukey’s honestly significant difference was used for 
post hoc analysis to determine which means were significantly different. 
	  	  	  
 
CHAPTER 4: RESULTS 
 
Body Composition 
Mice were divided into three groups, each fed a different diet lasting 12 weeks. The 
control diet (CD) group received standard rat chow where 14% of the total calories came from 
fat. Over 12 weeks, the control diet resulted in increases of total mass by 96% (Figure 4.1), fat 
mass by 216% (Figure 4.2), and fat-free mass by 24% (Figure 4.3), consistent with typical 
growth curves of young mice. The 3wkHF group was fed the control diet for 9 weeks and then a 
high-fat diet (60% kcal fat) for 3 weeks. Not surprisingly the body composition changes of the 
3wkHF group mimicked that of the CD for the first 9 weeks of the diet. Once the group started 
the high-fat diet total mass and fat mass increased drastically. By the end of 12 weeks, the 
3wkHF diet increased total mass by 72% (Figure 4.1), fat mass by 541% (Figure 4.2), and fat-
free mass by 27% (Figure 4.3). The 12wkHF group, which was fed the 60% fat diet for the entire 
12 weeks, gained the most total mass, fat mass, and fat free mass at 96%, 785%, and 33%, 
respectively. Both the 12wkHF and 3wkHF groups gained significantly more (p ≤ 0.05) total 
mass (Figure 4.1) and fat mass (Figure 4.2) than the CD. Fat mass was 2.78 fold higher in the 
12wkHF group and 2.18 fold higher in the 3wkHF group. Only the 12wkHF group gained 
significantly more fat-free mass (Figure 4.3). 
 
Blood Glucose, Serum Insulin, and Serum Myostatin 
Blood glucose and serum insulin were analyzed to estimate the presence of insulin 
resistance, a known complication of obesity14. While no significant differences were found 
among glucose measurements (Figure 4.4), serum insulin was higher than controls for the 
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3wkHF and 12wkHF groups, 287% and 910% respectively (Figure 4.5). However, because of 
the high variability of the 3wkHF group, a significant difference (p ≤ 0.05) was only found for 
the 12wkHF group. Myostatin is a well-known negative regulator of muscle mass21 and is 
increased during obesity17,18. Therefore, levels of serum myostatin were measured after each 12-
week diet. Myostatin of the 3wkHF group was not different than controls, but the 12wkHF group 
was significantly higher (p ≤ 0.05) at 123% (Figure 4.6).   
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Figure 4.1.  Changes in total body mass for the control group, 3-week high-fat group (3wkHF), 
and 12-week high-fat group (12wkHF) after each week of the study (means ± SE; 18-20 per 
group). *Significant difference at 12 weeks (p ≤ 0.05).  
  
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
35.0 
40.0 
45.0 
50.0 
0 3 6 9 12 
G
ra
m
s 
Weeks 
12 Wk 
3 Wk 
Control 
12wkHF 
3wkHF 
Control 
Body Mass 
* 
* 
* 
	  30	  	  
	  	  	  	  	  	  	  	  
Figure	  4.2.	  	  Changes	  in	  whole	  body	  fat	  mass	  for the control group, 3-week high-fat group 
(3wkHF), and 12-week high-fat group (12wkHF) after every third week of the study (means ± 
SE; 18-20 per group). *Significant difference at 12 weeks (p ≤ 0.05).  
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Figure	  4.3.	  	  Changes	  in	  whole	  body	  fat-­‐free	  mass	  for the control group, 3-week high-fat group 
(3wkHF), and 12-week high-fat group (12wkHF) after every third week of the study (means ± 
SE; 18-20 per group). *Significant difference at 12 weeks versus control and 3wkHF (p ≤ 0.05).  
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Figure	  4.4.	  	  Blood	  glucose	  for the control group, 3-week high-fat group (3wkHF), and 12-week 
high-fat group (12wkHF)	  at	  weeks (means ± SE; 18-20 per group). 	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Figure	  4.5.	  	  Serum	  insulin	  for the control group, 3-week high-fat group (3wkHF), and 12-week 
high-fat group (12wkHF) at 12 weeks (means ± SE; 18-20 per group). *Significant difference (p 
≤ 0.05) versus control and 3wkHF.	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Figure	  4.6.	  	  Serum	  myostatin	  for the control group, 3-week high-fat group (3wkHF), and 12-
week high-fat group (12wkHF)	  at 12 weeks (means ± SE; 18-20 per group). *Significant 
difference (p ≤ 0.05) versus control and 3wkHF.	    
0 
100 
200 
300 
400 
500 
600 
700 
800 
900 
CD CHF HF 
ρg
/m
L 
Serum Myostatin 
Control 3wkHF 12wkHF 
* 
	  35	  	  
Measures of Atrophy 
 
To determine whether a high-fat diet increased the weight of the hind limb muscles, 
individual innervated muscles of the lower hind limbs, representing extremes of fiber-type in the 
mouse, were removed and weighed. Weights of the innervated gastrocnemius, tibialis anterior 
(TA), and extensor digitorum longus (EDL) muscles of the 12wkHF group were 3% to 7% 
higher than the control or 3wkHF groups (Figure 4.7). Significant increases (p ≤ 0.05) were seen 
only in the plantaris and soleus muscles, which increase by 8% and 13%, respectively.  
The amount of muscle lost due to the denervation was determined by taking the 
difference between the innervated and denervated muscle masses, dividing it by the innervated 
muscle mass, and multiplying by 100 to obtain a percent atrophy. The soleus muscle of the 
3wkHF group was the only muscle to have a significantly higher (p ≤ 0.05) percent atrophy, 26% 
compared to 16% and 15% in the CD and 12wkHF groups (Figure 4.8). To rule out the 
possibility of excess water masking the atrophy response, the soleus and EDL muscles were 
dehydrated via an overnight freeze-dry to determine the percent water (Table 4.1). Both muscles 
of the 3wkHF and 12wkHF groups either contained the same or a less water than the control 
group, suggesting that the atrophy is a true loss of protein. 
To verify that the loss of muscle weight was due to atrophy of fibers (and not loss of the 
number of fibers), fiber size was measured by immunofluorescence microscopy. The tibialis 
anterior muscles were removed and 10 µm cross-sections were cut. The cross-sections were 
probed with an antilaminin antibody. The mean fiber areas of the denervated muscles were 
between 32% and 34% smaller than the innervated muscles as expected (Figure 4.9). There were 
no significant differences among the groups for either the innervated or denervated muscles, 
which is consistent with the findings for innervated muscle mass and percent atrophy. 
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 To determine whether atrophy was due to accelerated protein degradation, the soleus and 
extensor digitorum longus muscles were incubated for 2 hours in an oxygenated krebs bath. The 
amount of tyrosine released was quantified to establish the rate at which skeletal muscle proteins 
were being degraded. The rate of protein degradation was elevated in the denervated muscles as 
expected. There were no differences among the diet groups for the extensor digitorum longus, 
but the rate of protein degradation of the soleus muscle for the 3wkHF group was significantly 
higher (p ≤ 0.05) than both the control and 12wkHF groups by 30% (Figure 4.10). These 
findings are in agreement with the percent atrophy data.   
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Figure	  4.7.	  	  Muscle	  mass	  of	  the	  innervated	  gastrocnemius	  (Gastroc),	  tibialis	  anterior	  (TA),	  plantaris,	  extensor	  digitorum	  longus	  (EDL),	  and	  soleus	  for	  the	  control	  group,	  3-week high-
fat group (3wkHF), and 12-week high-fat group (12wkHF) (means ± SE; 18-20 per group).	  
*Significant difference (p ≤ 0.05) versus control and 3wkHF. 
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Figure	  4.8.	  Percent	  loss	  of	  muscle	  mass,	  reported	  as	  %	  atrophy,	  of	  the	  gastrocnemius	  (Gastroc),	  tibialis	  anterior	  (TA),	  plantaris,	  extensor	  digitorum	  longus	  (EDL),	  and	  soleus	  for	  the	  control	  group,	  3-week high-fat group (3wkHF), and 12-week high-fat group (12wkHF) 
(means ± SE; 8-10 per group).	  *Significant difference (p ≤ 0.05) versus control and 12wkHF. 
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Table	  4.1.	  Percent	  water	  of	  the	  Soleus	  (Table	  A)	  and	  Extensor	  Digitorum	  Longus	  (EDL)	  (Table	  B)	  muscles.	  	  
 	  	   	  
EDL Innervated Denervated 
Control 74.13 ± 0.25 76.32 ± 0.38 
3wkHF 73.97 ± 0.42 74.95 ± 0.45 
12wkHF 73.86 ± 0.45 74.91 ± 0.91 
Soleus Innervated Denervated 
Control 76.43 ± 0.53 77.52 ± 0.65 
3wkHF 74.61 ± 0.39 75.26 ± 0.71 
12wkHF 74.10 ± 0.37 73.19 ± 1.68 
A. 
B. 
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B. 
	  
Figure 4.9. Cross-sections of innervated and denervated tibialis anteriors from the control and 
12wkHF groups (Panel A) (Scale Bar = 50 µm). Fiber area of the tibialis anterior (Panel B) for 
the control group, 3-week high-fat group (3wkHF), and 12-week high-fat group (12wkHF) 
(means ± SE; 8-10 per group). *Significant difference (p ≤ 0.05) versus innervated. 	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Figure 4.10.	  	  Rate	  of	  protein	  degradation	  for	  the	  extensor	  digitorum	  longus	  (Panel	  A)	  and	  soleus	  (Panel	  B)	  of	  the	  control	  group,	  3-week high-fat group (3wkHF), and 12-week high-fat 
group (12wkHF) (means ± SE; 8-10 per group).	  *Significant difference (p ≤ 0.05) versus 
innervated. #Significant difference (p ≤ 0.05) versus control and 12wkHF, denervated.	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CHAPTER 5: DISCUSSION 
 
Summary of Findings 
 The major goal of our study was to determine if obesity changes the susceptibility of 
skeletal muscle to atrophy. Therefore, our diets were designed to induce short-term (3wkHF) or 
long-term (12wkHF) obesity. At 12 weeks with each diet, the 3wkHF group and 12wkHF group 
weighed significantly more than the control group (Figure 4.1). Differences in weight gain were 
largely attributed to increases in whole body fat mass, but fat-free mass was also significantly 
higher in the 12wkHF group (Figures 4.2 and 4.3). Although fat-free mass includes all non-fat 
tissue, increases in bone mass and other minerals is thought to have been minimal81, meaning 
that increases in fat-free mass should mainly be a result of increased muscle mass. Increased fat 
mass is a common result of a high-fat diet in C57BL/6 mice16,18,22,45,81,82. For example, Sitnick et 
al16 measured epididymal and retroperitoneal fat pads at the end of 14 weeks and saw increases 
of 117% and 106% above control values, respectively.  
Current literature has not provided a definitive answer on whether increased muscle mass 
is to be expected with a high-fat diet. Sitnick et al16 reported minor increases of 5% and 7% in 
the gastrocnemius and soleus, neither reaching significance, while Zhou et al22 showed 
significant decreases of 11% and 12% in the soleus and extensor digitorum longus. Both studies 
used a diet lower in fat (~40% kcal fat) than ours (60% kcal fat), but a crucial difference between 
our diet and the one used by Zhou et al22 was diet duration. A 12-week high-fat diet is sufficient 
to induce insulin resistance in a C57BL/6 mouse18, as demonstrated by our data (Figure 4.5). 
Zhou et al22 fed their mice a high-fat diet for 5 months. It is possible that these animals 
developed type II diabetes by the time of data collection. Unregulated type II diabetes is a 
condition well characterized by increased rates of protein degradation and decreased muscle 
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mass8. While increased mass overall is entirely consistent with other literature, increases in both 
fat and fat-free mass likely depend on factors such as diet composition and duration.  
Myostatin is a major negative regulator of skeletal muscle mass. In our study, serum 
myostatin of the 12wkHF, but not 3wkHF, was over 2 fold higher than the control group (Figure 
4.6). This finding is consistent with other studies in current literature. Lyons et al18 demonstrated 
in mice that a 12-week high-fat diet increased mRNA for myostatin in muscle 2.5 fold. Further, 
Hittel et al17 showed myostatin protein levels are increased in skeletal muscle and plasma from 
extremely obese humans. Considering that our findings agree with both human and rodent 
studies, our experimental design provides an excellent opportunity for studying how muscle 
mass is regulated during obesity. 
Mass of the innervated muscles tended to be higher in the 12wkHF group, but no 
differences were found for the amount of muscle lost or the rate of protein degradation due to 
denervation among any of the diet groups (Figures 4.7 – 4.10). The only exception was the 
higher percent atrophy and rate of protein degradation for the denervated soleus muscle of the 
3wkHF group. This goes against our hypotheses that the atrophy response will be reduced in the 
high-fat groups. As previously discussed, increased muscle mass is consistent with findings from 
Sitnick et al16, but not Zhou et al22. Sitnick et al did not measure rates protein degradation, but 
Zhou et al showed increases of 18% and 25% in basal protein degradation for the soleus and 
extensor digitorum longus, respectively22. Again, these differences may be a result of the 
prolonged diet condition. Currently, no studies have examined how muscles of the obese react 
when atrophy is induced. Sitnick et al16 did induce hypertrophy by functionally overloading the 
plantaris muscle and found obese mice hypertrophied 16% less than controls. They also found 
that a high-fat diet inhibited the pathway responsible for increasing protein synthesis16. In light 
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of this, it would seem that obese muscle would respond to atrophy by losing more muscle mass. 
However, our hypotheses were based on a second possibility, that obese individuals may not be 
as efficient at controlling amino acid metabolism in general. If this were the case, the muscle of 
the obese would atrophy less. Our data, though disproving our hypotheses, shows that muscle 
exposed to long-term (12-week) obesity is no more susceptible to atrophy induced by 
denervation than lean muscle. These findings are surprising considering that increased 
expression of myostatin alone has been shown to induce atrophy20. These mice were exposed to 
over 2 fold more myostatin than their lean counterparts yet they did not atrophy more (Figure 
4.8); in fact, they tended to increase muscle mass (Figure 4.7).  
While no differences were found for measures of atrophy between the control and 
12wkHF groups, the soleus muscle of the 3wkHF group had a rate of protein degradation 30% 
higher and lost 10% more mass (Figure 4.10 and 4.8). Under our model, circulating factors such 
as insulin, free fatty acids, cytokines, and myostatin are presumably the same for all muscles. 
Therefore, why these differences exist between muscles is unclear. However, it could be related 
to the fiber type distribution of the soleus muscle in comparison to other muscles of a rodent hind 
limb. The soleus is highly oxidative and contains the highest percentage of type I fibers at about 
58%34. This is a point of interest because Type I fibers have a tremendous resistance to most 
types of atrophy. When exposed to starvation42 or excess corticosteroids41, conditions known to 
induce atrophy, type I fibers only lose about 8% of their mass whereas type II fibers lose over 
30% of their mass. Conversely, when type I fibers are exposed to denervation41 the amount of 
mass lost increases to around 30%. Another point to consider is that a short-term high-fat diet 
causes oxidative adaptations in skeletal muscle. de Wilde et al45 showed that after a 4-week high-
fat diet, rodent skeletal muscle increased protein for type I myosin heavy chain and complexes I-
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V of the electron transport chain. It is possible that this shift towards a more oxidative profile 
may have increased the soleus’s susceptibility to denervation. To test this theory one could 
conduct a study using a similar short-term (3-week) high-fat diet and induce atrophy using 
excess corticosteroids, for example. If the fiber-type differences are no longer apparent, it 
suggests that an increased oxidative profile may in fact be making the soleus more sensitive to 
denervation. 
Mice fed a typical long-term high-fat diet, 12 to 14 weeks, have over twice the 
concentration of circulating myostatin as controls, yet they do not appear to increase basal 
protein degradation or atrophy more in response to denervation. This suggests that these mice 
have become resistant to the effects of myostatin and may not be able to regulate muscle mass in 
the same manner as controls. What is causing this resistance is not known, but it could involve 
the metabolic inflexibility commonly associated with obesity12,15. Metabolic inflexibility refers 
to an individual’s inability to switch between different substrates, even when the cellular 
environment favors a specific substrate12. The most notable form of metabolic inflexibly is 
insulin resistance, which impairs glucose and lipid metabolism14.  It is reasonable to suspect that 
an additional component of metabolic inflexibility might be the inability to mobilize amino acids 
and it could be due in part to this myostatin resistance. 
 
Clinical Relevance 
 Muscle mass and obesity has become a topic of interest over that last decade. This may 
be due in part to the congruent emergence of the obesity paradox and sarcopenic obesity. The 
obesity paradox refers to how obese individuals are at higher risk of developing chronic diseases 
than lean individuals, but they tend to live longer once the incident of disease occurs83. This is 
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particularly true for individuals who are classified by their body mass index (BMI) as overweight 
(BMI of 25 – 29.9 kg/m2) or grade 1 obese (BMI of 30 – 34.9 kg/m2)84. If an individual crosses 
into obesity grades 2 (BMI of 35 – 39.9 kg/m2) or 3 (BMI ≥ 40 kg/m2), mortality increases84. 
Mortality increases even higher if muscle mass is decreased, a condition known as sarcopenic 
obesity85.   
 The reason the obesity paradox exists is unclear, but two theories have been suggested. 
First, disease states are often characterized by an increased state of catabolism causing energy 
requirements to drastically increase48. The increased adiposity of an obese individual allows 
them to survive longer while leaner individuals become malnourished and succumb to the 
disease sooner86. Secondly, it may be due to the genetic disposition of the leaner individual 
becoming sick in the first place. Obesity induced disease may be associated with better outcomes 
in general, where as a lean individual who develops disease due to genetic factors may be more 
susceptible from the beginning86.  
 Since the genetic background of the mice in our study is identical between groups, our 
data supports the first theory. During a highly catabolic state it is typical for skeletal muscle to be 
degraded to mobilize amino acids for synthesizing proteins for antibodies or rebuilding damaged 
tissue48. In a healthy individual after the amino acid demand returns to normal, skeletal muscle 
mass is replenished by a dietary source of amino acids48. When an individual becomes sick the 
demand for protein is so high that dietary sources, including amino acid supplementation, is not 
enough to maintain muscle mass48. Eventually muscle mass is degraded to a point where it can 
no longer support vital metabolic processes and the person dies48.  
Our data might shed some light on the obesity paradox as it suggests that obese skeletal 
muscle is not as readily degraded by elevated levels of myostatin as lean skeletal muscle, 
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allowing obese individuals to survive longer with disease. Considering that myostatin is 
abundant in many of the disease states associated with muscle wasting7,51,87,88, this resilience may 
be associated with the apparent myostatin resistance seen in our mice. If the mechanisms behind 
myostatin resistance could be established, perhaps a new target area for treating muscle wasting 
in all populations could be developed.  
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